Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 3/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.37 |
| ▸ | DRD4 | P21917 | 10/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24764354 | 1.00 | PDK1 (0.48) | PDK1HRH3DRD4GBA1 | |
| SCHEMBL22837616 | 0.89 | PDK1 (0.41) | PDK1HRH3DRD4GBA1 | |
| SCHEMBL26403991 | 0.89 | PDK1 (0.41) | PDK1HRH3DRD4GBA1 | |
| SCHEMBL22856298 | 0.89 | PDK1 (0.36) | PDK1HRH3DRD4GBA1 | |
| SCHEMBL21106060 | 0.89 | PDK1 (0.36) | PDK1HRH3DRD4GBA1 | |
| SCHEMBL21107633 | 0.89 | PDK1 (0.36) | PDK1HRH3DRD4GBA1 | |
| SCHEMBL25654283 | 0.87 | PDK1 (0.35) | PDK1HRH3DRD4GBA1 | |
| SCHEMBL25654280 | 0.87 | PDK1 (0.35) | PDK1HRH3DRD4GBA1 | |
| SCHEMBL26280856 | 0.87 | PDK1 (0.51) | PDK1HRH3DRD4 | |
| SCHEMBL26280853 | 0.87 | PDK1 (0.51) | PDK1HRH3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | PDK1 477/4885HRH3 3763/4885DRD4 3828/4885 |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PDK1 504/4885HRH3 3631/4885DRD4 4363/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PDK1 504/4885HRH3 3631/4885DRD4 4363/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PDK1 504/4885HRH3 3631/4885DRD4 4363/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | PDK1 1229/4885HRH3 4371/4885DRD4 2524/4885 |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | PDK1 2127/4885HRH3 3052/4885DRD4 2372/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PDK1 504/4885HRH3 3631/4885DRD4 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.